OCT tops the list of the leading CROs in 3Q 2017

Thursday, November 2, 2017

According to the Synergy Research Group report, the most active CRO in the region were OCT, Quintiles, PSI, Synergy Research Group and IPHARMA. OCT has been working with the largest number of patients during this period. AbbVie tops the list of the leaders among foreign pharmaceutical companies, which initiated clinical trials in 3Q, while Biocad and Severnaya Zvezda were named the most active among Russian companies.

[Read More]

BioLineRx, I-Bridge Capital establish China joint venture

Friday, August 26, 2016

BioLineRx, a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, has established a joint venture (JV) with I-Bridge Capital, a Chinese venture capital fund focused on developing innovative therapies in China. The joint venture, named iPharma, will develop innovative clinical and preclinical therapeutic candidates originating primarily in Israel to serve the Chinese and global healthcare markets. 

[Read More]